EUVIMEDEUVIMED entdecken
Crossref

Long-lasting Rivaroxaban Use Is Associated With Lower Aortic Valve Leaflet Calcification in Severe Aortic Stenosis

Magdalena Kopytek, Jacek Tarasiuk, Sebastian Wroński, Piotr Mazur, Michał Ząbczyk, Anetta Undas, Joanna Natorska

Canadian Journal of Cardiology · 2025

DOI: 10.1016/j.cjca.2025.06.068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Cardiology, 2025. Verfasst von Magdalena Kopytek und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Centre for Medical R…. Hauptthemen laut MEDLINE: Rivaroxaban, Aortic Valve Stenosis, Aortic Valve, Calcinosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In vitro studies have demonstrated that direct oral anticoagulants (DOACs) downregulate expression of proteins involved in calcification and inflammation. In this hypothesis-testing study we evaluated whether DOAC therapy was associated with decreased valvular calcification in patients with aortic stenosis (AS) who were anticoagulated due to concomitant atrial fibrillation (AF). METHODS: In this case-control study, 72 Caucasian patients with isolated severe AS were compared with 53 individuals with AF concomitant to severe AS who were treated with DOACs for 28.7 ± 13.8 months. Sixteen valves from AS patients on rivaroxaban (20 mg/day, AS-RIVA group) and 20 valves from age- and sex-matched non-anticoagulated patients with AS were subjected to microcomputed tomography (micro-CT) to estimate valvular calcification ex vivo. Calcium volume (CV), surface volume (SV), CV/SV ratio, and trabecular thickness (TbTh) were assessed. Valvular expression of osteopontin, nuclear factor-kappaB (NF-κB), and interleukin-6 (IL-6) were evaluated by immunostaining. RESULTS: Micro-CT showed that patients taking rivaroxaban had a lower CV (-62.7%), lower SV (-46.2%), decreased CV/SV ratio (-35.6%), and maximal TbTh (-21.1%) when compared with patients not taking the drug (P < 0.05 for all). The duration of rivaroxaban use correlated inversely with micro-CT parameters, peak transvalvular velocity, and maximal transvalvular pressure gradient. Decreased valvular expression of osteopontin (-20.4%) and NF-κB (-26%) and 2-fold lower IL-6 fluorescence intensity were observed in the AS-RIVA group compared with the remainder (P < 0.05 for all). Moreover, osteopontin expression was inversely associated with duration of rivaroxaban use and positively with micro-CT parameters. CONCLUSIONS: Long-term rivaroxaban use in AS patients was associated with lower aortic valve leaflet calcification, -as reflected by micro-CT parameters, and osteopontin expression, suggesting a potential impact of rivaroxaban on valvular calcification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanAortic Valve StenosisAortic ValveCalcinosisHumansFemaleMaleFactor Xa InhibitorsAgedCase-Control StudiesSeverity of Illness IndexX-Ray MicrotomographyAtrial FibrillationMiddle Aged

Stichwörter der Autor:innen

aortic stenosiscalcificationdirect oral anticoagulantsmicrocomputed tomographyosteopontinrivaroxaban

Substanzen

RivaroxabanFactor Xa Inhibitors

Autor:innen und Institutionen

  • Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Centre for Medical Research and Technologies, St. John Paul II Hospital, Krakow, Poland.
  • Department of Condensed Matter Physics, Faculty of Physics and Applied Computer Science, AGH University of Science and Technology, Krakow, Poland.
  • Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; University Department of Cardiac Surgery, Heart Center Leipzig, Leipzig, German…
  • Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Centre for Medical Research and Technologies, St. John Paul II Hospital, Krakow, Poland. E…

Förderung

  • Narodowe Centrum Nauki

Zitieren

APA

Kopytek, M., Tarasiuk, J., Wroński, S., Mazur, P., Ząbczyk, M., Undas, A., & Natorska, J. (2025). Long-lasting Rivaroxaban Use Is Associated With Lower Aortic Valve Leaflet Calcification in Severe Aortic Stenosis. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2025.06.068

Vancouver

Kopytek M, Tarasiuk J, Wroński S, Mazur P, Ząbczyk M, Undas A, et al. Long-lasting Rivaroxaban Use Is Associated With Lower Aortic Valve Leaflet Calcification in Severe Aortic Stenosis. Canadian Journal of Cardiology. 2025. doi:10.1016/j.cjca.2025.06.068

BibTeX
@article{Kopytek2025,
  author = {Kopytek, Magdalena and Tarasiuk, Jacek and Wroński, Sebastian and Mazur, Piotr and Ząbczyk, Michał and Undas, Anetta and Natorska, Joanna},
  title = {Long-lasting Rivaroxaban Use Is Associated With Lower Aortic Valve Leaflet Calcification in Severe Aortic Stenosis},
  journal = {Canadian Journal of Cardiology},
  year = {2025},
  doi = {10.1016/j.cjca.2025.06.068}
}
Kostenlos starten →